Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07890376) titled 'A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes' on Oct. 16.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Eli Lilly and Company
Condition:
Obesity
Overweight
Intervention:
Drug: LY4086940
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 2026
Target Sample Size: 460
Countries of Recruitment:
United States
Argentina
United States
To know...